检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:容春莉[1] 姚文静[1] 杨倩[1] 李如意[1] 曹东平[1] 刘美霞[1] 彭应心[1]
机构地区:[1]河北省人民医院心脏中心,河北石家庄050051
出 处:《山东大学学报(医学版)》2015年第11期46-49,共4页Journal of Shandong University:Health Sciences
基 金:河北省科技攻关计划项目(03276196D-54)
摘 要:目的探讨阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症患者的临床疗效与安全性。方法选取2013年5月至2014年2月收治的冠状动脉粥样硬化并高脂血症患者82例,根据就诊顺序随机分为单用组和联用组,每组41例。单用组采用阿托伐他汀钙治疗,20 mg/次,1次/d。联用组在此基础上加用依折麦布,10 mg/次,1次/d。比较两组治疗12周后降脂效果差异。结果治疗前单用组与联用组总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、C反应蛋白(CRP)值无明显差异(P>0.05),治疗后两组TC、TG、LDL-C、CRP值较治疗前均显著降低,HDL-C显著增高(P<0.05),联用组较单用组变化更加显著(P<0.05)。联用组LDL-C达标率(78.05%)显著高于单用组(53.66%)(P<0.05)。两组治疗前后肝功能、肾功能指标变化差异无统计学意义(P>0.05)。结论阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的降脂效果更显著,同时不会加重肝肾负担。Objective To investigate the clinical efficiency and safety of atorvastatincalcium combined with ezetimibe for treating coronary atherosclerosis with hyperlipidemia. Methods A total of 82 cases of coronary atherosclerosis with hyperlipidemia treated in our hospital during May 2013 to Feb. 2014 were collected and divided into two groups. Patients in single drug group (n = 41 ) were treated with atorvastatincalcium only, while patients in the combined drug group (n =41 ) received atorvastatincalcium and ezetimibe. After 12 weeks, lipid contents of the two groups were com- pared. Results Before the treatment, the values of TC, TG, HDL-C, LDL-C, and CRP in the two groups were not significantly different ( P 〉 0.05 ). After the treatment, the values of TC, TG, LDL-C, CRP in the two groups were markedly reduced and HDL-C was remarkably increased than before ( P 〈 0.05 ), and the improvement was greater in the combined drug group (P 〈0.05). The standard rate of LDL-C was 78.05% in combined drug group, which was notably higher than that of the single drug group (53.66%) ( P 〈 0.05 ). There were no differences in liver and renal function between the two groups before and after treatment ( P 〉 0.05 ). Conclusion Atorvastatincalcium combined with ezetimibe has significant lipid-lowering effect in treating coronary atherosclerosis with hyperlipidemia, and does not increase the burden on liver and kidney.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222